Moroni G, et al. - Clinical efficacy and safety of low-dose rituximab (RTX) therapy in primary membranous nephropathy (PMN) was assessed in a multicentric prospective study. Findings reported that in <50% of PMN cases, low-dose RTX obtained remission. Data also suggested that higher doses and longer treatments were most likely required to induce and maintain a response. Notably, selection of the patient and the optimal dosage should be guided by the balance between the costs and benefits.